Combining first and subsequent sites of recurrence, brain involvement was present in 40% of patients with documented recurrence of HR-/HER2+ breast cancer and in 33% of patients with documented recurrence of HR+/HER2+ tumors. Here, ERBB2 is linked to breast carcinoma.